Daniel J Weiss,Amy L Ryan
Daniel J Weiss
Human mesenchymal stromal cell extracellular vesicles maintain therapeutic miRNA cargo despite exposure to cystic fibrosis bronchoalveolar lavage fluid [0.03%]
人源间充质基质细胞外泌体维持其microRNA治疗载荷，即使暴露于囊性纤维化支气管肺泡灌洗液中也是如此
Sara Rolandsson Enes,Thomas H Hampton,Jayita Barua et al.
Sara Rolandsson Enes et al.
Background and aims: Human bone marrow-derived mesenchymal stromal cells (hBM-MSCs) and their extracellular vesicles (EVs) reduce lung inflammation and fibrosis in a variety of model systems, including in a Cystic Fibrosi...
Nonviral transposon‑engineered stem cells characterization: dose‑dependency between vector copy number and transgene expression [0.03%]
非病毒转座子工程干细胞的特征研究：载体拷贝数与转基因表达之间的剂量依赖关系
Wanzhu Zhao,Brittany Mihelich,Baoyan Fan et al.
Wanzhu Zhao et al.
Genetically engineered stem cells hold substantial promises for advancing regenerative medicine, yet ensuring their genomic safety remains a critical challenge. A key safety concern is vector copy number (VCN), which defines the number of i...
Isolation of adipose-derived mesenchymal stromal cells expressing soluble forms of GAS1 and PTEN for experimental cell therapy for glioblastoma [0.03%]
用于胶质母细胞瘤实验性细胞治疗的表达GAS1和PTEN可溶形式的脂肪源性间充质基质细胞的分离
Gisela Tovar-Medina,Carla Daniela Florán-Hernández,José Arturo Avalos-Fuentes et al.
Gisela Tovar-Medina et al.
Background aims: Glioblastoma is the most frequent primary brain tumor, and its current treatment mainly prolongs survival, highlighting the need for more effective second-line therapies to improve patient prognosis. Stem...
Nutritional and immunologic scoring systems to predict complications and outcomes after anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma [0.03%]
用于预测抗B细胞成熟抗原嵌合抗原受体T细胞治疗后复发/难治性多发性骨髓瘤患者并发症和结果的营养和免疫评分系统
Xuezhu Xu,Zujie Lin,Rui Liu et al.
Xuezhu Xu et al.
Background aims: Chimeric antigen receptor (CAR) T-cell therapy has significant benefits in the treatment of relapsed/refractory multiple myeloma (R/R MM). Despite the established correlation between nutritional status an...
Litigating the hype: the Lung Health Institute class action and its implications [0.03%]
穿透性诉讼的迷雾：LungHealthInstitute集体诉讼案及其影响
Mark Alonzo,Bambi J Grilley,Daniel J Weiss et al.
Mark Alonzo et al.
The recent Lung Institute class action lawsuit is used as an example of patient-initiated lawsuits regarding unproven "stem cell" interventions. Current regulatory considerations for administration and advertisement of cell therapies are co...
Uncovering molecular and functional dynamics of human hematopoietic stem cells during in vitro culture for cell therapy manufacturing [0.03%]
体外培养过程中人类造血干细胞分子和功能动力学的揭示以用于细胞治疗制造
Juliana Xavier-Ferrucio,Matthew Ung,Fulton Norman et al.
Juliana Xavier-Ferrucio et al.
Background: Background: Hematopoietic stem/progenitor cell (HSPC) transplantation outcomes depend critically on the dose of functional stem cells delivered to patients, yet current ex vivo cell therapy manufacturing proce...
A scoping review of gene editing in clinical trials: identifying aspects of trial design to accelerate clinical adoption [0.03%]
临床试验中的基因编辑定位综述：识别试验设计的各方面以加速临床应用
Gabrielle Khare,An Duong,Justine Hanotaux et al.
Gabrielle Khare et al.
Background: Initial clinical trials of gene editing have recently emerged and generated significant interest in this promising therapy. A scoping review is needed to understand aspects of study design that may accelerate ...
Understanding FDA's reasons for nonapproval: A systematic review of complete response letters in cell and gene therapy [0.03%]
美国食品和药物管理局拒绝细胞和基因治疗申请的原因分析：对完整反应信的系统性回顾
Eugene Babcock,Cindy Riggins
Eugene Babcock
Background aims: Cell and gene therapy products face unique regulatory challenges due to their biological complexity and the stringent expectations for manufacturing control, analytical testing, and clinical assessment. A...
Platinum TALEN-mediated nonviral gene editing facilitates clinical-scale production of cancer antigen-reactive T cells [0.03%]
铂金TALEN介导的非病毒基因编辑可促进肿瘤抗原反应性T细胞的临床规模生产
Kayo Toishigawa,Kenta Magoori,Hiroyuki Sato et al.
Kayo Toishigawa et al.
Background aims: Recently, target-genome editing has emerged as a next-generation tool for the clinical development of designed cellular products. Although Clustered Regularly Interspaced Short Palindromic Repeats-Cas9 (C...